Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors
January 08 2020 - 8:00AM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led
biopharmaceutical company focused on immuno-inflammatory diseases,
today announced the appointment of Vincent Milano to its board of
directors, effective January 7, 2020.
Vincent Milano has served as the President and Chief Executive
Officer, and as a member of the board of directors, of Idera
Pharmaceuticals, Inc., a publicly held biopharmaceutical company,
since December 2014. Prior to joining Idera, between 1996 and 2014,
Mr. Milano served in increasingly senior roles at ViroPharma Inc.,
a pharmaceutical company that was acquired by Shire Plc in 2014,
most recently as Chairman, President and Chief Executive Officer
from 2008 to 2014. Prior to joining ViroPharma, Mr. Milano served
in increasingly senior roles, most recently as a senior manager, at
KPMG LLP, an independent registered public accounting firm, from
1985 to 1996. Mr. Milano also served on the board of directors of
ViroPharma from 2008 to 2014, Spark Therapeutics, Inc. from 2014 to
2019 and Vanda Pharmaceuticals Inc. from 2010 to 2019. Mr. Milano
currently serves on the board of directors of VenatoRx
Pharmaceuticals, Inc., a private company, and Life Sciences Cares
Philadelphia, a non-profit organization. Mr. Milano holds a
Bachelor of Science degree in Accounting from Rider College.
“We are pleased to welcome Vin to the Aclaris Board of
Directors. His extensive operational and business development
experience will be invaluable as we continue to progress our small
molecule kinase inhibitor pipeline for immuno-inflammatory
diseases,” said Dr. Neal Walker, President and Chief Executive
Officer of Aclaris. We look forward to leveraging Vin’s deep
experience and leadership to help guide Aclaris as we continue to
execute on our new strategic direction.” About Aclaris
Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a physician-led biopharmaceutical
company committed to addressing the needs of patients with
immuno-inflammatory diseases who lack satisfactory treatment
options. The company’s diverse and multi-stage portfolio includes
one late-stage investigational drug candidate and a pipeline
powered by a robust R&D engine exploring protein kinase
regulation. For additional information, please visit
www.aclaristx.com and follow Aclaris on LinkedIn or Twitter
@aclaristx. Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
"believe," "expect," "may," "plan," "potential," "will," and
similar expressions, and are based on Aclaris’ current beliefs and
expectations. These forward-looking statements include expectations
regarding the development of Aclaris’ pipeline. These statements
involve risks and uncertainties that could cause actual results to
differ materially from those reflected in such statements. Risks
and uncertainties that may cause actual results to differ
materially include uncertainties inherent in the conduct of
clinical trials, Aclaris’ reliance on third parties over which it
may not always have full control, and other risks and uncertainties
that are described in the Risk Factors section of Aclaris’ Annual
Report on Form 10-K for the year ended December 31, 2018, the Form
10-Q for the quarter ended September 30, 2019 and other filings
Aclaris makes with the U.S. Securities and Exchange Commission from
time to time. These documents are available under the "SEC filings”
section of the Investors page of Aclaris’ website at
http://www.aclaristx.com. Any forward-looking statements speak only
as of the date of this press release and are based on information
available to Aclaris as of the date of this release, and Aclaris
assumes no obligation to, and does not intend to, update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Aclaris ContactMichael Tung, M.D.Senior Vice
President Corporate Strategy/Investor
Relations484-329-2140mtung@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Sep 2023 to Sep 2024